Repligen (RGEN) Tops Q4 EPS by 10c, Guidance Falls Short of Conensus

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.68, $0.10 better than the analyst estimate of $0.58. Revenue for the quarter came in at $186.8 million versus the consensus estimate of $186.3 million.

GUIDANCE:

Repligen sees FY2023 EPS of $2.61-$2.69, versus the consensus of $2.92. Repligen sees FY2023 revenue of $760-800 million, versus the consensus of $800 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight